bioZhena Corporation is a medical device pre-revenue company with revolutionary diagnostic technology for the women's healthcare market. SEE QUICK INTRO 4 SLIDES: https://v.gd/hx7vv6We seek capital with which to launch within 2 years the already FDA-approved first Ovulona application (the Ovulona™ f…
bioZhena Corporation is a medical device pre-revenue company with revolutionary diagnostic technology for the women's healthcare market.
SEE QUICK INTRO 4 SLIDES: https://v.gd/hx7vv6
We seek capital with which to launch within 2 years the already FDA-approved first Ovulona application (the Ovulona™ for couples trying to conceive and their physicians), and to finalize the Smart Ovulona™ and the Halo™ for launch. Sustained marketing and profitability will require further capital injection, hence the two planned tranches of financing ($7M and $13M).
Monitoring the cervix uteri yields superior information that is more reliable than all current commercially-available approaches to fertility monitoring. They only focus a woman-user on trying to conceive but cannot be used for pregnancy avoidance, and cannot provide the other benefits of Ovulona™ use.
SaaS subscription business model will be employed to introduce the planned new applications and upgrades. The hardware will not change thus enhancing the high profit margin inherent in the design.
PLEASE NOTE: Our development stage is pre-revenue, post proof-of-concept. Planned use of sought startup capital: Generate revenues with the FDA-cleared product, and prepare for Smart Ovulona™ and Halo™ launch.
Women’s reproductive healthcare is a substantial market that can lead to multi-billion dollar revenues. Detailed financial modeling of the commercialization of the bioZhena technology asset leads to NPVs in excess of $1Billion.
Our core product, the Ovulona™, is a personal hand-held vaginal monitor that utilizes proprietary bioelectronic measurements of the outer tissues of the cervix. No chemicals are used. Significant research precedent exists for electrometric monitoring of cervical tissues - but only in complex clinical settings. This FDA-approved fertility monitor is affordable and simple to use, thus empowering women with the ability to control their reproduction both for achieving pregnancy and for birth control without the use of hormones.
In addition to the breakthrough ability to serve for birth control, the Ovulona™ will provide a number of related benefits including the built-in immediate detection of pregnancy and of early pregnancy loss, baby gender selection by timing of conception, assessment of the full-term birth date, and detection of a condition predictive of premature labor/birth.
As a reminder, pre-term labor and pre-term births cost the US healthcare system in excess of $26B/year, and an early warning method like the Ovulona™ could reduce those expenditures substantially by allowing health care providers to intervene with much less costly treatments leading to improved pregnancy outcomes. We believe that this potential for cost savings will be a substantial factor in achieving insurance coverage for our technology, which enhances commercial viability.
Our monitoring of the cervical tissues has significant implications for healthcare beyond the management of conception. The Ovulona™ monitor will be gradually positioned as a management tool for various conditions related to the monitored menstrual cycling biology, as regulatory requirements are met by clinically testing the new applications.
This will include automatic and innocuous cervical health screening (for pre-cancerous conditions and for sexually transmitted infections), and Ovulona profiling for peri-menopause management (e.g. personalized HRT), PCOS, LPD, Infertility of Unknown Etiology and other women’s health issues, from teen age (dysmenorrhea, sex education, smoking cessation biofeedback) to menopause.
For more information on this pre-revenue company with strong IP and management team, please email me to schedule a conversation.
Vaclav Kirsner, PhD vaclav@biozhena.com
LinkedIn profile with attachments: https://www.linkedin.com/profile/preview?locale=en_US&trk=prof-0-sb-preview-primary-button
Team (1)
Sectors bioZhena Corporation serves:
Health Care
Consumer Goods
Join Axial's Private M&A Platform
bioZhena Corporation connects with qualified M&A advisors through the Axial Platform.
Looking for Buyers?
Reach this investor and hundreds more on Axial. No cost to advisors.
